Two drugs are better than one to start T2DM therapy (original) (raw)

DIABETES

Nature Reviews Endocrinology volume 16, pages 15–16 (2020)Cite this article

Subjects

Early and intensive glycaemic control protects patients with type 2 diabetes mellitus (T2DM) from the development of late cardiovascular complications. The authors of the VERIFY trial now show that a more durable attainment of HbA1c <7% is observed by adding vildagliptin to metformin as starting therapy in newly diagnosed patients with T2DM.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Fig. 1: Proposal for merging the glucocentric and the cardiocentric view of T2DM treatment.

References

  1. [No authors listed.] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
  2. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
    Article CAS Google Scholar
  3. Laiteerapong, N. et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 42, 416–426 (2019).
    Article CAS Google Scholar
  4. Brown, J. B., Conner, C. & Nichols, G. A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33, 501–506 (2010).
    Article CAS Google Scholar
  5. Phung, O. J. et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 16, 410–417 (2014).
    Article CAS Google Scholar
  6. Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519–1529 (2019).
    Article CAS Google Scholar
  7. Schnell, O. et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc. Diabetol. 18, 30 (2019).
    Article Google Scholar
  8. Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669–2701 (2018).
    Article Google Scholar
  9. Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehz486 (2019).
  10. Abdul-Ghani, M. & DeFronzo, R. A. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care 40, 1121–1127 (2017).
    Article CAS Google Scholar

Download references

Acknowledgements

The authors thank the Italian Ministry of Health (Ricerca Corrente), who supported part of this work.

Author information

Authors and Affiliations

  1. Department of Cardiovascular and Dysmetabolic Diseases, IRCCS MultiMedica, Milano, Italy
    Francesco Prattichizzo, Lucia La Sala & Antonio Ceriello

Authors

  1. Francesco Prattichizzo
    You can also search for this author inPubMed Google Scholar
  2. Lucia La Sala
    You can also search for this author inPubMed Google Scholar
  3. Antonio Ceriello
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toAntonio Ceriello.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

About this article

Cite this article

Prattichizzo, F., La Sala, L. & Ceriello, A. Two drugs are better than one to start T2DM therapy.Nat Rev Endocrinol 16, 15–16 (2020). https://doi.org/10.1038/s41574-019-0294-3

Download citation

This article is cited by